Rizafilm

(rizatriptan)

PreclinicalSmall molecule

OOrganon and Co

Rizafilm is one of 6 small molecule programs targeting Headache. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Patents

Pipeline

Status by Indication[3][1]

Indication

Motion SicknessActive, not recruiting

Motion SicknessPreclinical

Active, not recruiting

Competition

Competitive Landscape

5 competitors in Motion Sickness

#DrugCompanyPhaseTrials

Sufenta

LLeaf Vertical Inc.

Approved

1 2

Advil

KKenvue Brands

Approved

1 3

Nereus

VVanda Pharmaceuticals

Phase 3

4 4

Phenergan

BBassett Healthcare

Approved

1 5

Other

AstraZeneca

Phase 2

1 6

Rizafilm

OOrganon and Co

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Migraine8 trials

A Dose-Finding Study of MK0974 in Acute Migraine (MK0974-004)

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT00246337·420 enrolled

Maximizing Outcomes in Treating Acute Migraine

Completed·AAxsome Therapeutics, Inc.·Phase 3·NCT03896009·1,594 enrolled

Rizatriptan for Episodic Dizziness in Vestibular Migraine

Completed·—·Phase 2/3·NCT02447991·223 enrolled

Show 5 more trials

Rizatriptan 10 MG RPD in the Treatment of Acute Migraine

Completed·UUniversität Duisburg-Essen·Phase 4·NCT01057160·195 enrolled

A Study to Evaluate the Efficacy and Tolerability of Rizatriptan for Treatment of Acute Migraine in Children and Adolescents (MK-0462-082 AM7)

Completed·OOrganon and Co·Phase 3·NCT01001234·1,382 enrolled

Two Rizatriptan Prescribing Portions for Treatment of Migraine

Completed·CClinvest·Phase 4·NCT00397254·197 enrolled

Telcagepant (MK-0974) Long-Term Safety Study in Adult Participants With Acute Migraine (MK-0974-012)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT00443209·1,068 enrolled

A Study to Evaluate the Efficacy and Tolerability of Rizatriptan for Treatment of Acute Migraine (0462-087)

Completed·OOrganon and Co·Phase 3·NCT00894556·109 enrolled

Motion Sickness1 trial

Does a Migraine Medication Decrease Rotational Motion Sickness in People Suffering From Migraines?

Completed·UUniversity of Pittsburgh·N/A·NCT00360282·36 enrolled

Oral1 trial

Long-Term Exposure to Rizatriptan 5-mg and 10-mg Oral Tablet (Combined Extension Protocols MK-0462-022, MK-0462-025, MK-0462-029)

Completed·OOrganon and Co·Phase 3·NCT01286207·1,959 enrolled

Headache1 trial

Study of Rizatriptan in the Treatment of Acute Attacks of Post-traumatic Headache in U.S. Military Troops

Withdrawn·HHenry M. Jackson Foundation for the Advancement of Military Medicine·N/A·NCT01306266

Regulatory

FDA Approval Timeline[4]

Jun 29, 1998

MAXALT-MLT

NDA NDA020865

Jun 29, 1998

MAXALT

NDA NDA020864

Feb 26, 2026

RIZAFILM

NDA NDA205394

Sources

References

[1]
ClinicalTrials.gov — 11 trial records for rizatriptan. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — rizatriptan compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for rizatriptan. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA205394). U.S. Food & Drug Administration.
[5]
FDA Orange Book — Patent and exclusivity data for Rizafilm. U.S. Food & Drug Administration.
[6]
SEC EDGAR — Organon and Co company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: OOrganon and Co

Patent Landscape[5]

Patent Cliff

Jul 30, 2034

Earliest patent expiration — generic entry possible after this date

Patent #Expires

9301948Jul 30, 2034

Rizafilm

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Migraine8 trials

Motion Sickness1 trial

Oral1 trial

Headache1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Patent Landscape[5]

Related News